← Back to patent-cliff list
ALX-1
Tier C — Watch / tradeALX-1
Vast Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Bronchiectasis, Respiratory disease, 多重耐药感染, 分支杆菌感染, Pseudomonas infection, Mycobacterium avium-intracellulare complex disease
Regional status
US
Phase I
2025-11-18
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ALX-1?
Approved indications include: Bronchiectasis, Respiratory disease, 多重耐药感染, 分支杆菌感染, Pseudomonas infection, Mycobacterium avium-intracellulare complex disease.
When does the ALX-1 patent expire?
No public expiry year is available for ALX-1 yet; this page updates once verified.
How do I get a quote for ALX-1 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29